About: Herpes simplex virus and Cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Herpes simplex virus and Cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Herpes simplex virus and Cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO
Creator	Forel, Jean-Marie Papazian, Laurent Roch, Antoine Adda, Mélanie Fabre, Cyprien Guervilly, Christophe Hraiech, Sami Bonnardel, Eline Cavaille, Guilhem Coiffard, Benjamin Loundou, Anderson Parzy, Gabriel
source	PMC
abstract	BACKGROUND: Herpesviridae reactivation among non-immunocompromised critically ill patients is associated with impaired prognosis, especially during acute respiratory distress syndrome (ARDS). However, little is known about herpes simplex virus (HSV) and Cytomegalovirus (CMV) reactivation occurring in patients with severe ARDS under veno-venous extracorporeal membrane oxygenation (ECMO). We tried to determine the frequency of Herpesviridae reactivation and its impact on patients’ prognosis during ECMO for severe ARDS. RESULTS: During a 5-year period, 123 non-immunocompromised patients with a severe ARDS requiring a veno-venous ECMO were included. Sixty-seven patients (54%) experienced HSV and/or CMV reactivation during ECMO course (20 viral co-infection, 40 HSV alone, and 7 CMV alone). HSV reactivation occurred earlier than CMV after the beginning of MV [(6–15) vs. 19 (13–29) days; p < 0.01] and after ECMO implementation [(2–8) vs. 14 (10–20) days; p < 0.01]. In univariate analysis, HSV/CMV reactivation was associated with a longer duration of mechanical ventilation [(22–52.5) vs. 17.5 (9–28) days; p < 0.01], a longer duration of ECMO [15 (10–22.5) vs. 9 (5–14) days; p < 0.01], and a prolonged ICU [29 (19.5–47.5) vs. 16 (9–30) days; p < 0.01] and hospital stay [44 (29–63.5) vs. 24 (11–43) days; p < 0.01] as compared to non-reactivated patients. However, in multivariate analysis, viral reactivation remained associated with prolonged MV only. When considered separately, both HSV and CMV reactivation were associated with a longer duration of MV as compared to non-reactivation patients [29 (19.5–41) and 28 (20.5–37), respectively, vs. 17.5 (9–28) days; p < 0.05]. Co-reactivation patients had a longer duration of MV [58.5 (38–72.3); p < 0.05] and ICU stay [51.5 (32.5–69) vs. 27.5 (17.75–35.5) and 29 (20–30.5), respectively] as compared to patients with HSV or CMV reactivation alone. In multivariate analysis, HSV reactivation remained independently associated with a longer duration of MV and hospital length of stay. CONCLUSIONS: Herpesviridae reactivation is frequent among patients with severe ARDS under veno-venous ECMO and is associated with a longer duration of mechanical ventilation. The direct causative link between HSV and CMV reactivation and respiratory function worsening under ECMO remains to be confirmed.
has issue date	2019-12-23(xsd:dateTime)
bibo:doi	10.1186/s13613-019-0616-6
bibo:pmid	31872319
has license	cc-by
sha1sum (hex)	17a2301f5673e08a8830da3081504b9791323de5
schema:url	https://doi.org/10.1186/s13613-019-0616-6
resource representing a document's title	Herpes simplex virus and Cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO
has PubMed Central identifier	PMC6928167
has PubMed identifier	31872319
schema:publication	Ann Intensive Care
resource representing a document's body	covid:17a2301f5673e08a8830da3081504b9791323de5#body_text
is schema:about of	named entity 'patients' named entity 'ARDS' named entity 'ECMO' named entity 'Herpesviridae' named entity 'herpes simplex virus (HSV)' named entity 'acute respiratory distress syndrome (ARDS)' named entity 'CMV' named entity 'ARDS' named entity 'patients' named entity 'immunocompromised' named entity 'ECMO' named entity 'Herpesviridae' named entity 'ARDS' named entity 'ARDS' named entity 'acute respiratory distress syndrome' named entity 'extracorporeal membrane oxygenation' named entity 'ARDS' named entity 'ECMO' named entity 'ECMO' named entity 'CMV' named entity 'plasma levels' named entity 'ARDS' named entity 'ICU' named entity 'risk of death' named entity 'ICU' named entity 'prognosis' named entity 'ICU' named entity 'ICU' named entity 'HIV' named entity 'immunocompromised patients' named entity 'ARDS' named entity 'CMV' named entity 'CMV' named entity 'fever' named entity 'Clinical outcomes' named entity 'univariate analysis' named entity 'ECMO' named entity 'acute respiratory distress syndrome' named entity 'CMV' named entity 'CMV' named entity 'HSV' named entity 'HSV' named entity 'CMV' named entity 'CMV' named entity 'immunosuppression' named entity 'ARDS' named entity 'HSV' named entity 'ECMO' named entity 'HSV' named entity 'transfusion' named entity 'ICU' named entity 'ARDS' named entity 'Student's t test' named entity 'ECMO' named entity 'IBM SPSS Statistics' named entity 'case-control study' named entity 'corticosteroid therapy' named entity 'ARDS' named entity 'Herpesviridae' named entity 'ECMO' named entity 'HSV' named entity 'Organ Failure' named entity 'Clinical outcomes' named entity 'ICU' named entity 'mechanical ventilation' named entity 'antiviral treatment' named entity 'ECMO' named entity 'human immunodeficiency virus' named entity 'IBM' named entity 'immunocompromised'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software